Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-06-20T00:15:04.640Z Has data issue: false hasContentIssue false

Anxiolytics

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Jonas, J. M., Cohon, M. S. (1993). A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. J Clin Psychiatry, 54 Suppl., 2545; discussion 4648.Google ScholarPubMed
Liver Toxicology. (2012). Benzodiazepines. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (eds.). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases.Google Scholar
Ait-Daoud, N., Hamby, A. S., Sharma, S., et al. (2018). A review of alprazolam use, misuse, and withdrawal. J Addict Med, 12, 410.CrossRefGoogle ScholarPubMed
DeVane, C. L., Ware, M. R., Lydiard, R. B. (1991). Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull, 27, 463473.Google Scholar
Olivier, J. D. A., Olivier, B. (2020). Translational studies in the complex role of neurotransmitter systems in anxiety and anxiety disorders. Adv Exp Med Biol, 1191, 121140.CrossRefGoogle ScholarPubMed
Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google ScholarPubMed
Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476483.CrossRefGoogle ScholarPubMed
Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 10231033.CrossRefGoogle ScholarPubMed
Spiegel, D. A. (1998). Efficacy studies of alprazolam in panic disorder. Psychopharmacol Bull, 34, 191195.Google Scholar
Klein, E. (2002). The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry, 63 Suppl. 14, 2733.Google ScholarPubMed
No authors listed. (2019). Drugs for anxiety disorders. Med Lett Drugs Ther, 61, 121126.Google Scholar
Greenblatt, D. J., Wright, C. E. (1993). Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet, 24, 453471.CrossRefGoogle ScholarPubMed

References

Stahl, S. M. (2017). Buspirone. In Stahl’s Essential Psychopharmacology Prescriber’s Guide (eds.). Cambridge: Cambridge University Press, pp. 113115.Google Scholar
Amneal Pharmaceuticals LLC. (2019). Buspirone Package Insert. Bridgewater, New Jersey.Google Scholar
Mahmood, I., Sahajwalla, C. (1999). Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet, 36, 277287.CrossRefGoogle ScholarPubMed
Mezher, A. W., McKnight, C. A., Caplan, J. P. (2019). Buspirone abuse: no safe haven. Psychosomatics, 60, 534535.Google Scholar

References

Liver Toxicology. (2012). Benzodiazepines. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (eds.). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases.Google Scholar
Stahl, S. M. (2017). Clonazepam. In Stahl’s Essential Psychopharmacology Prescriber’s Guide (eds.). Cambridge: Cambridge University Press, pp. 159163.Google Scholar
Sandoz Inc. (2019). Clonazepam Package Insert. Princeton, New Jersey.Google Scholar
Volz, A., Khorsand, V., Gillies, D., et al. (2007). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 24(1), CD006391.Google Scholar
Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google ScholarPubMed
Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476483.CrossRefGoogle ScholarPubMed
Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 10231033.CrossRefGoogle ScholarPubMed
Gillies, D., Sampson, S., Beck, A., et al. (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, 24(1), CD003079.Google Scholar
Dodds, T. J. (2017). Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord, 19, doi 10.4088CrossRefGoogle Scholar
Zaman, H., Sampson, S., Beck, A., et al. (2018). Benzodiazepines for psychosis-induced aggression or agitation. Schizophr Bull, 44, 966969.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Benzodiazepine Protocol. Sacramento, California.Google Scholar
DeVane, C. L., Ware, M. R., Lydiard, R. B. (1991). Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull, 27, 463473.Google ScholarPubMed
No authors listed. (2019). Drugs for anxiety disorders. Med Lett Drugs Ther, 61, 121126.Google Scholar

References

Oceanside Pharmaceuticals Inc. (2017). Diazepam Gel Package Insert. Bridgewater, New Jersey.Google Scholar
Stahl, S. M. (2017). Diazepam. In Stahl’s Essential Psychopharmacology Prescriber’s Guide (eds.). Cambridge: Cambridge University Press, pp. 211215.Google Scholar
Civica. (2019). Diazepam Injection Package Insert. London (UK).Google Scholar
Mayne Pharma. (2019). Diazepam Tablets Package Insert. London (UK).Google Scholar
Olivier, J. D. A., Olivier, B. (2020). Translational studies in the complex role of neurotransmitter systems in anxiety and anxiety disorders. Adv Exp Med Biol, 1191, 121140.CrossRefGoogle ScholarPubMed
Volz, A., Khorsand, V., Gillies, D., et al. (2007). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11 CD006391.CrossRefGoogle Scholar
Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar
Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476483.CrossRefGoogle ScholarPubMed
Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 10231033.CrossRefGoogle ScholarPubMed
Gillies, D., Sampson, S., Beck, A., et al. (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, 9, CD003079.CrossRefGoogle Scholar
Dodds, T. J. (2017). Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord, 19, doi 10.4088CrossRefGoogle Scholar
Zaman, H., Sampson, S., Beck, A., et al. (2018). Benzodiazepines for psychosis-induced aggression or agitation. Schizophr Bull, 44, 966969.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Benzodiazepine Protocol. Sacramento, CaliforniaGoogle Scholar
Liver Toxicology. (2012). Benzodiazepines. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (eds.). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases.Google Scholar

References

Stahl, S. M. (2017). Hydroxyzine. In Stahl’s Essential Psychopharmacology Prescriber’s Guide (eds.). Cambridge: Cambridge University Press, pp. 331334.Google Scholar
Avet Pharmaceuticals Inc. (2020). Hydroxyzine Package Insert. East Brunswick, New Jersey.Google Scholar
Paton, D. M., Webster, D. R. (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet, 10, 477497.CrossRefGoogle ScholarPubMed

References

Stahl, S. M. (2017). Lorazepam. In Stahl’s Essential Psychopharmacology Prescriber’s Edition (eds.). Cambridge: Cambridge University Press, pp. 403407.Google Scholar
Qualitest Pharmaceuticals Inc. (2018). Lorazepam Tablets Package Insert. Huntsville, Alabama.Google Scholar
Amneal Pharmaceuticals LLC. (2019). Lorazepam Concentrate Package Insert. Bridgewater, New Jersey.Google Scholar
International Medication Systems. (2019). Lorazepam Injection Package Insert. South El Monte, California.Google Scholar
Volz, A., Khorsand, V., Gillies, D., et al. (2007). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar
Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar
Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476483.CrossRefGoogle ScholarPubMed
Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 10231033.CrossRefGoogle ScholarPubMed
Gillies, D., Sampson, S., Beck, A., et al. (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, 9, CD003079.CrossRefGoogle Scholar
Dodds, T. J. (2017). Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord, 19, doi: 10.4088CrossRefGoogle Scholar
Zaman, H., Sampson, S., Beck, A., et al. (2018). Benzodiazepines for psychosis-induced aggression or agitation. Schizophr Bull, 44, 966969.CrossRefGoogle ScholarPubMed
Liver Toxicology. (2012). Benzodiazepines. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (eds.). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Benzodiazepine Protocol. Sacramento, California.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Anxiolytics
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Anxiolytics
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Anxiolytics
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×